Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Maintaining Outstanding Outcomes Using Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma: A Report From the Children's Oncology Group Study ANBL0531.
Twist CJ, Schmidt ML, Naranjo A, London WB, Tenney SC, Marachelian A, Shimada H, Collins MH, Esiashvili N, Adkins ES, Mattei P, Handler M, Katzenstein H, Attiyeh E, Hogarty MD, Gastier-Foster J, Wagner E, Matthay KK, Park JR, Maris JM, Cohn SL. Twist CJ, et al. Among authors: adkins es. J Clin Oncol. 2019 Dec 1;37(34):3243-3255. doi: 10.1200/JCO.19.00919. Epub 2019 Aug 6. J Clin Oncol. 2019. PMID: 31386611 Free PMC article. Clinical Trial.
Outcome of high-risk stage 3 neuroblastoma with myeloablative therapy and 13-cis-retinoic acid: a report from the Children's Oncology Group.
Park JR, Villablanca JG, London WB, Gerbing RB, Haas-Kogan D, Adkins ES, Attiyeh EF, Maris JM, Seeger RC, Reynolds CP, Matthay KK; Children's Oncology Group. Park JR, et al. Among authors: adkins es. Pediatr Blood Cancer. 2009 Jan;52(1):44-50. doi: 10.1002/pbc.21784. Pediatr Blood Cancer. 2009. PMID: 18937318 Free PMC article. Clinical Trial.
Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study.
Matthay KK, Reynolds CP, Seeger RC, Shimada H, Adkins ES, Haas-Kogan D, Gerbing RB, London WB, Villablanca JG. Matthay KK, et al. Among authors: adkins es. J Clin Oncol. 2009 Mar 1;27(7):1007-13. doi: 10.1200/JCO.2007.13.8925. Epub 2009 Jan 26. J Clin Oncol. 2009. PMID: 19171716 Free PMC article. Clinical Trial.
Defining Risk Factors for Chemotherapeutic Intervention in Infants With Stage 4S Neuroblastoma: A Report From Children's Oncology Group Study ANBL0531.
Twist CJ, Naranjo A, Schmidt ML, Tenney SC, Cohn SL, Meany HJ, Mattei P, Adkins ES, Shimada H, London WB, Park JR, Matthay KK, Maris JM. Twist CJ, et al. Among authors: adkins es. J Clin Oncol. 2019 Jan 10;37(2):115-124. doi: 10.1200/JCO.18.00419. Epub 2018 Nov 16. J Clin Oncol. 2019. PMID: 30444686 Free PMC article. Clinical Trial.
Long-term follow-up of patients with intermediate-risk neuroblastoma treated with response- and biology-based therapy: A report from the Children's Oncology Group study ANBL0531.
Barr EK, Naranjo A, Twist CJ, Tenney SC, Schmidt ML, London WB, Gastier-Foster J, Adkins ES, Mattei P, Handler MH, Matthay KK, Park JR, Maris JM, Desai AV, Cohn SL. Barr EK, et al. Among authors: adkins es. Pediatr Blood Cancer. 2024 Aug;71(8):e31089. doi: 10.1002/pbc.31089. Epub 2024 May 31. Pediatr Blood Cancer. 2024. PMID: 38822537
Evaluation of Image-Defined Risk Factor (IDRF) Assessment in Patients With Intermediate-risk Neuroblastoma: A Report From the Children's Oncology Group Study ANBL0531.
Brown EG, Adkins ES, Mattei P, Hoffer FA, Wootton-Gorges SL, London WB, Naranjo A, Schmidt ML, Hogarty MD, Irwin MS, Cohn SL, Park JR, Maris JM, Bagatell R, Twist CJ, Nuchtern JG, Davidoff AM, Newman EA, Lal DR. Brown EG, et al. Among authors: adkins es. J Pediatr Surg. 2025 Jan;60(1):161896. doi: 10.1016/j.jpedsurg.2024.161896. Epub 2024 Sep 6. J Pediatr Surg. 2025. PMID: 39317567 Free article.
15 results